Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away. Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away. Economic Times
January 24, 2025
- ExThera Claimed Its Device Could Cure Cancer. But Patients Died.
- Trump’s executive orders might threaten growth of electric vehicles and wind power
- Remembering Margarethe Hilferding, the First Woman Admitted to Freud’s Vienna Psychoanalytic Society
- The Neuroscience of Severance: What’s Real? What’s Fake?
Headlines
